In June last year, we outlined the key exclusivity provisions in the 21st Century Cures Act. Then in July 2015, we reported that the House of Representatives passed a form of the Act by a vote of 344-77.
Although the Senate has received and read it twice, the Act was ultimately passed back to the Committee on Health, Education, Labor, and Pensions. Today, NPR reported that a refined version of this Act may be on the verge of passage in the House again with a vote set for this Wednesday.
While final details are still being negotiated, Kaiser Health News reported that “the House version that passed in June 2015 provided the National Institutes of Health $1.75 billion in additional annual funding over five years. The bill would keep generics off the market longer for drugs treating rare diseases and speed the drug and device approval process.”
Stay tuned to Big Molecule Watch as we continue to monitor this developing story.